Anticoagulation Length in Cancer Associated Thrombosis (ALICAT)
Not Applicable
Completed
- Conditions
- Cancer Associated ThrombosisCirculatory System
- Registration Number
- ISRCTN37913976
- Lead Sponsor
- Cardiff University (UK)
- Brief Summary
2014 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/24726032 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26490434
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
1. Receiving low-molecular-weight heparin (LMWH) for treatment of Cancer Associated Thrombosis (CAT) for five months
2. Locally advanced or metastatic cancer
3. Able to self-administer LMWH, or have LMWH administered by a carer
4. Able to give informed consent
5. Age =18 years
Exclusion Criteria
1. Receiving drug other than LMWH for CAT
2. Contraindication to anticoagulation
2.1. Known allergies to LMWHs, heparin, sulfites or benzyl alcohol
2.2. Active major bleeding
2.3. History of heparin-induced thrombocytopenia
3. Confirmed recurrent VTE whilst receiving anticoagulation
4. Female patients who are pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method